Clinical Trial Update: Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing tesetaxel every 3 weeks vs weekly dosing and capecitabine as first-line therapy for locally advanced or metastatic breast cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• tesetaxel (tesetaxel)

Snippet

Sponsor: Genta Incorporated | Conditions: Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN